ArticleMedicine2025
Network pharmacology and molecular docking to elucidate the mechanism of antiaging of Platycodon grandiflorus.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPlatycodon grandiflorus (PG) is a traditional Chinese medicinal herb widely cultivated in China. Although studies have demonstrated its effects in combating aging, the specific mechanisms underlying these effects have rarely been reported. This study utilized network pharmacology and molecular docking techniques to explore the active components of PG and its potential antiaging mechanisms.
methodsActive components of PG sourced from the traditional Chinese medicine systems pharmacology database, as well as the targets of active components and aging culled from databases like GeneCards, and their common targets were presented using a Venn diagram. Common targets were imported into the STRING database for protein-protein interaction analysis, and core targets were defined, which were enriched for Kyoto Encyclopedia of Genes and Genomes pathways. Molecular docking between active components and targets was performed using AutoDockTools software.
resultsOur findings unveiled a total of 264 targets correspond to 7 active ingredients of PG, as well as 2906 potential targets related to aging, of which 152 were common targets. Among these common targets, 10 core targets have been identified as potentially playing a role in the antiaging effects of PG. Kyoto Encyclopedia of Genes and Genomes enrichment analysis of these targets revealed that PG regulates the aging process through various pathways, such as estrogen signaling pathway, lipid and atherosclerosis pathway, and apoptosis pathway. Molecular docking analysis further demonstrated a robust binding affinity between the active component acacetin and the antiaging targets CASP3 and SRC, as well as between spinasterol and the target ESR1.
conclusionIn summary, through this research, we screened information pertaining to PG's active components and initially predicted potential targets and pathways for its antiaging effects, which required further experimental verification, however, our study provided a solid theoretical foundation for subsequent research on PG's antiaging mechanisms and the development of related products.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.